Priya SR1, Anand A2, Keshri S3, Garg S4 and Dandekar M4*
1Head Neck Surgeon, India
2Department of Medical Oncology, Paras Cancer Centre, India
3Department of Radiation Oncology, Paras Cancer Centre, India
4Department of Surgical Oncology, Paras Cancer Centre, India
The occurrence of locoregional recurrences, distant metastasis and second primaries has limited the efficacy of treatment for oral cancer. Despite improvements and modifications in treatment paradigms, there has not been significant reduction in the numbers of post treatment disease events in such patients. The research on antiangiogenesis which began systematically in the 1970s
has evolved to a point where several agents have been approved for treatment of cancers such as lung, colon, breast and thyroid. Some of these drugs are being used as combination therapy for oral cancers also, while others are being investigated by clinical trials. This review covers the principles of angiogenesis, its mechanisms and its history; we give an overview of the current scenario of use of antiangiogenic drugs for oral cancers. The use of angiogenesis inhibitors in chemoprevention for oral premalignant lesions is examined and future directions are discussed.
Angiogenesis; Antiangiogenic agents; Oral cancer; Oral premalignant lesions; Chemoprevention; VEGF
Priya SR, Anand A, Keshri S, Garg S, Dandekar M. An Enquiry on the Present Status of Drugs Inhibiting Neo-Angiogenesis in the Treatment of Oral Cancers. Clin Oncol. 2022;7:1924..